Analysts showing optimistic trends for: Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Nick Sanchez
March 4, 2017

A number of other research firms also recently weighed in on VRX. Deutsche Bank AG set a $24.00 price target on shares of Valeant Pharmaceuticals International and gave the company a "hold" rating in a research report on Sunday, November 20th.

While looking at the Stock's Performance, Valeant Pharmaceuticals International, Inc. now shows a Weekly Performance of -17.07%, where Monthly Performance is -0.22%, Quarterly performance is -19.87%, 6 Months performance is -54.55% and yearly performance percentage is -79.62%. Morgan Stanley dropped their price target on shares of Valeant Pharmaceuticals International from $42.00 to $25.00 and set an "overweight" rating for the company in a research report on Thursday, November 10th. The 1-year price target of the company is 21.34. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 2.36 on a scale of 1-5.

Analysts and investors may use different metrics in order to calculate a price target projection.

Shares of Valeant Pharmaceuticals Intl (TSE: VRX) opened at 18.41 on Wednesday. The company's market capitalization is $4.78 billion. Valeant Pharmaceuticals International, Inc. has a one year low of $13.00 and a one year high of $101.40. The firm has a 50-day moving average of $14.90 and a 200 day moving average of $19.81.

(NYSE: VRX) reported its last quarter results on 02/28/2017.

Important factors to focus when evaluating a stock's present and future value are the 52-week price high and low levels. The fiscal year 2016 current estimate trend was for $2.32 as compared to FY 2017 current Estimate trends of $2.64. Valeant Pharmaceuticals International had a positive return on equity of 43.81% and a negative net margin of 22.17%.

Shares of Valeant Pharmaceuticals International, Inc. Kistler Tiffany Companies LLC increased its position in shares of Valeant Pharmaceuticals Intl by 95.5% in the third quarter. On average, equities research analysts expect that Valeant Pharmaceuticals Intl will post $4.17 EPS for the current year.

This news story was originally reported by The Cerbat Gem and is the sole property of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and republished in violation of global copyright laws. The original version of this piece can be accessed at https://www.com-unik.info/2017/03/03/valeant-pharmaceuticals-intl-inc-vrx-receives-market-perform-rating-from-bmo-capital-markets.html. Also, Director Pershing Square Capital Manage sold 3,476,690 shares of Valeant Pharmaceuticals Intl stock in a transaction on Monday, December 12th. The stock was sold at an average price of $14.85, for a total transaction of $51,628,846.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

In other news, Director Thomas W. Sr. Ross purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, December 14th. The average numbers of shares are traded in a security per day, during the recent 3-month period. Capstone Asset Management Co. now owns 26,408 shares of the specialty pharmaceutical company's stock valued at $648,000 after buying an additional 360 shares during the last quarter. The disclosure for this purchase can be found here.

A number of institutional investors have recently bought and sold shares of the stock. US Bancorp DE boosted its stake in shares of Valeant Pharmaceuticals Intl by 141.0% in the third quarter. Phoenix Investment Adviser LLC now owns 93,900 shares of the specialty pharmaceutical company's stock worth $2,305,000 after buying an additional 11,800 shares during the period. Finally, Advisor Group Inc. boosted its position in shares of Valeant Pharmaceuticals Intl by 6.3% in the third quarter. (NYSE: VRX) is now showing its ROA (Return on Assets) of -4.7%. Finally, Shell Asset Management Co. increased its position in shares of Valeant Pharmaceuticals International by 2.2% in the second quarter.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. Public Sector Pension Investment Board raised its position in Valeant Pharmaceuticals Intl by 3.1% in the fourth quarter. Its price to free cash flow for trailing twelve months is 12.39 and Current ratio for the most recent quarter of 1.50.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, David Steinberg and Chris Schott have a yearly average return of 2.3% and 4.1% respectively.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company.

Other reports by Ligue1talk

Discuss This Article

FOLLOW OUR NEWSPAPER